Mitochondrionopathy phenotype in doxorubicin-treated Wistar rats depends on treatment protocol and is cardiac-specific

• Published in: PloS one Vol. 7; no. 6; p. e38867
• Main Authors: Pereira, Gonçalo C, Pereira, Susana P, Pereira, Claudia V, Lumini, José A, Magalhães, José, Ascensão, António, Santos, Maria S, Moreno, António J, Oliveira, Paulo J
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 22-06-2012; Public Library of Science (PLoS)
• Subjects: Animal models; Animal tissues; Animals; Anthracyclines; Antibiotics; Antibiotics, Antineoplastic - adverse effects; Aqueous solutions; Biocompatibility; Bioenergetics; Biology; Cancer therapies; Cardiotoxicity; Doxorubicin; Doxorubicin - adverse effects; Drug dosages; Electron transport; Exercise; Heart; Heart - drug effects; Heart diseases; Hypotheses; In vivo methods and tests; Kidney - drug effects; Kidney - metabolism; Kidneys; Laboratory animals; Life sciences; Liver; Liver - drug effects; Liver - metabolism; Male; Medicine; Mitochondria; Mitochondria, Heart - drug effects; Mitochondrial DNA; Myocardium - metabolism; Neurosciences; Oxidation; Oxidative stress; Permeability; Physical fitness; Rats; Rats, Wistar; Respiration; Rodents; Studies; Toxicity; Portugal
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0038867

Although doxorubicin (DOX) is a very effective antineoplastic agent, its clinical use is limited by a dose-dependent, persistent and cumulative cardiotoxicity, whose mechanism remains to be elucidated. Previous works in animal models have failed to use a multi-organ approach to demonstrate that DOX-associated toxicity is selective to the cardiac tissue. In this context, the present work aims to investigate in vivo DOX cardiac, hepatic and renal toxicity in the same animal model, with special relevance on alterations of mitochondrial bioenergetics. To this end, male Wistar rats were sub-chronically (7 wks, 2 mg/Kg) or acutely (20 mg/Kg) treated with DOX and sacrificed one week or 24 hours after the last injection, respectively. Alterations of mitochondrial bioenergetics showed treatment-dependent differences between tissues. No alterations were observed for cardiac mitochondria in the acute model but decreased ADP-stimulated respiration was detected in the sub-chronic treatment. In the acute treatment model, ADP-stimulated respiration was increased in liver and decreased in kidney mitochondria. Aconitase activity, a marker of oxidative stress, was decreased in renal mitochondria in the acute and in heart in the sub-chronic model. Interestingly, alterations of cardiac mitochondrial bioenergetics co-existed with an absence of echocardiograph, histopathological or ultra-structural alterations. Besides, no plasma markers of cardiac injury were found in any of the time points studied. The results confirm that alterations of mitochondrial function, which are more evident in the heart, are an early marker of DOX-induced toxicity, existing even in the absence of cardiac functional alterations.